Currently Enrolling Studies

Studies for people with memory loss

Alzheimer's Disease Ketogenic Diet Retention and Feasibility Trial (KDRAFT)  The purpose of this study is to evaluate if patients with Alzheimer's disease can stay on a very low carbohydrate (ketogenic) diet and if this diet is beneficial in Alzheimer's disease. The study duration is 4 months where participants will consume a ketogenic diet for 3 months. Study procedures include blood draws, cognitive testing, DEXA scans, MRI's and questionnaires. Participants will be compensated a total of $125 upon study completion. All participants are required to have a study partner for participation in this research study. Funding for this study is provided by a grant from Frontiers Pilot and Collaborative Studies Funding Program and the University of Kansas Alzheimer's Disease Center Pilot Program.

Therapeutic Effects of Intranasally-administered Insulin (INI) in Adults with Amnestic Mild Cognitive Impairment (aMCI) or Mild Alzheimer's Disease (SNIFF) This study is enrolling participants who have mild Alzheimer's Disease (AD) or mild cognitive impairment (MCI) due to AD in a trial to determine if cognitive functioning can be improved after treatment with insulin, administered at home with an intranasal inhaler.  Study procedures include MRI's, pen and paper thinking tests, interviews/questionnaires, blood draws for lab tests, physical and neurological exams, ECG's, and lumbar punctures. Those who qualify will be randomized to receive insulin or placebo for 12 months, followed by a 6 month open label period in which all participants will receive insulin.  Participants will attend 8 study visits over the course of 18 months and will be compensated $25 for each visit completed, with an additional $100 for each of the 2 lumbar puncture procedures. STUDY IS CURRENTLY ON HOLD

MK 8931-017 (EPOCH) This study is evaluating the safety and efficacy of a study medication for treatment of Alzheimer's Disease.  Participants in this study will take an oral medication once daily for 18 months and come to the clinic for approximately 10 visits throughout the study.   Study procedures include MRI's, ophthalmology exams, ECG's, pen and paper thinking tests, blood draws for lab tests, and questionnaires/interviews.  Participants will be compensated $100 and their study partners will be compensated $50 for each study visit completed.  This study is sponsored by Merck Sharp & Dohme Corp.  

A Phase 2 multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of T-817MA in patients with mild to moderate Alzheimer's Disease  (TCAD) TCAD is a clinical study designed to evaluate whether the investigational drug T-817MA, a neuroprotective agent, has the potential to slow decline in memory and daily functioning in people with Alzheimer's disease. The study will enroll those with mild-to-moderate AD who are 55-85 years old.  Participants in this study must have been taking donepezil (Aricept®) for at least 6 months prior to enrollment and will be asked to remain on donepezil throughout the study.  Study procedures include questionnaires, pen and paper thinking tests, blood draws, ECG's, physical exams, and MRI's (a CT scan maybe  substituted if participants are not able to have MRI's due to pacemakers or other reasons).  Compensation of $25 is provided for each study visit completed, for a total of $300 for completing all study visits.  

S-Equol in Alzheimer's Disease (SEAD)  SEAD is a study designed to help determine if S-equol, a compound that acts like estrogen in the body, causes an increase in brain mitochondrial activity, which researchers believe could help to slow the progression of Alzheimer's disease (AD).  This early phase study will also help to determine if S-Equol is safe and tolerable in people with AD.  To qualify for the study, you must be female, age 60-90, have a diagnosis of mild AD , and NOT be taking any type of estrogen replacement therapy.  The study involves 4 visits to the clinic over the course of a 6 week period.  Procedures include vital signs, blood draws, pen and paper thinking tests, and questions about any changes in your health. Participants will receive $50 for each study visit completed for a total of $200 if all visits are completed.

Supporting Family Caregivers with Technology for Dementia Home Care (FamTechCare) This study will test whether in-home monitoring and expert feedback on behavior problems will reduce stress, reduce behavior frequency and improve caregiver confidence over 3 months.  We will provide you an iPad mini, visit your home to set up the iPad mini and train you to use software to record the situations.  You choose which situations to videotape and submit to the experts for their review.  We will come back to your home at 1 month and 3 months of participation.  Internet connection is required for study participation.

Studies for people without memory loss

Alzheimer's Prevention Program (APP)   This new study is a comprehensive research effort to examine strategies to improve health and reduce your risk for chronic diseases, including Alzheimer's disease. We are now enrolling participants 65 years and older without Alzheimer's or dementia for the Alzheimer's Prevention Program (APP). One of the goals of the APP is to learn about potential risk factors and what protective behaviors can effectively reduce the risk of developing Alzheimer's disease. The program focuses on how exercise and nutrition influence healthy and unhealthy aging. Study subjects will receive a risk assessment with an amyloid PET scan, general health screen, healthy lifestyle prescription, and surveillance examinations at follow ups.

Effect of Aerobic Exercise on Alzheimer's Pathophysiology in Preclinical AD (APEX) This study will examine the effects of aerobic exercise in individuals at high risk for Alzheimer's Disease, as determined by an amyloid brain imaging scan.  Participants must be age 65 or older, have normal cognition, be physically underactive/sedentary, and be identified at screening with brain imaging tests to have the protein called amyloid.   Those who qualify will be randomized to either an aerobic exercise group or a control group.  This study will observe whether 52 weeks of aerobic exercise will be associated with lower amyloid levels in the brain, as measured by imaging tests.

Anti-Amyloid Treatment in Asymptomatic Alzheimer's (A-4) This is a study for older individuals who may be at risk for developing memory loss due to Alzheimer's disease (AD), but who do not currently have symptoms of AD.  The A4 study is examining an investigational medicine, Solanezumab, which may reduce the impact of a protein known as "amyloid" forming plaques in the brain. Scientists believe that accumulation of amyloid in the brain may play a key role in the eventual development of Alzheimer's disease (AD) -related memory loss.  This investigational medicine targets amyloid build-up in the brain with the aim of slowing memory loss associated with the development of AD.  Participants in this study must be ages 65-85 with normal thinking and memory function but with evidence of amyloid plaque buildup in the brain, as determined by a PET brain imaging test.   Study procedures include PET brain imaging, MRI brain imaging, ECG's, blood draws for lab work, physical and neurological exams, memory and thinking tests, and questionnaires/interviews.  A lumbar puncture procedure is optional. Compensation for each study visit completed will be provided.

Studies for people with and without memory loss

None Currently Enrolling.

Last modified: Mar 20, 2015
How to Join

Want to be considered
for a study?

Complete this form

Questions? Contact us at or call 913-588-0555.